J. Michael Pearson

J. Michael Pearson founded the modern Valeant Pharmaceuticals entity in 2001, implementing a radical acquisition-driven business model that relied on debt financing to purchase mature pharmaceutical brands and cut R&D expenditures. His defining moment was the execution of the $8.7 billion acquisition of Biogen Idec's dermatology unit in 2009, which established the template for the aggressive, serial acquisition strategy that would temporarily make Valeant one of the largest pharmaceutical companies in the world before the 2015 pricing scandal.

J. Michael Pearson is a Canadian businessman and former CEO of Valeant Pharmaceuticals, who served as the company's chief executive from 2008 to 2016. He played a pivotal role in the company's aggressive expansion, navigating the complex debt financing structures provided by Pershing Square and Oaktree Capital to execute a series of transformational acquisitions. Pearson's background as a McKinsey consultant gave him a unique perspective on the pharmaceutical industry, driving his focus on financial engineering and cost-cutting rather than internal drug discovery. During his tenure, he oversaw the acquisition of over 50 companies, including Coria Laboratories, Medicis, and Salix Pharmaceuticals, which generated tens of billions of dollars in cumulative revenue. Pearson was also known for his controversial pricing strategies, which sparked public outrage and led to a massive SEC investigation and a 96% collapse in the company's stock price in 2015. Despite the controversy, Pearson is widely credited with transforming Valeant from a struggling niche player into a global pharmaceutical powerhouse, although his legacy is permanently tarnished by the regulatory and reputational damage caused by his aggressive tactics.